Cost-effectiveness of long-acting insulin analogues vs intermediate/long-acting human insulin for type 1 diabetes: A population-based cohort followed over 10 years.

Tsung-Ying LeeShihchen KuoChen-Yi YangHuang-Tz Ou

Published in: British journal of clinical pharmacology (2020)

This real-world evidence reveals that compared with ILAHI, the greater pharmaceutical costs associated with LAIAs for patients with T1D could be substantially offset by savings from averted hypoglycaemia or diabetes-related complications.

Keyphrases

type diabetes
glycemic control
endothelial cells
cardiovascular disease
insulin resistance
risk factors
molecular docking
weight loss
metabolic syndrome
adipose tissue
skeletal muscle
drug induced